PD-L1 Expression As a Predictive Biomarker for Immune Checkpoint Inhibitors: Between a Dream and a Nightmare
Immunotherapy(2021)SCI 4区
St Joseph Univ Beirut
Abstract
PD-L1 is an important predictive biomarker for treatment by immune checkpoint inhibitors (ICIs). ICIs are now indicated for the treatment of various cancer depending on the level of expression of PD-L1 on tumor cells. PD-L1 testing is done using immunohistochemistry with five different assays approved as companion diagnostic for ICIs. However, these assays have different score reporting methods and do not accurately measure PD-L1 expression. Exosomal PD-L1 testing has recently emerged as an alternative for cell-surface PD-L1 testing however studies are still premature and more extensive knowledge about this new potential biomarker is needed.
MoreTranslated text
Key words
28-8,73-10,anti-PD-1,anti-PD-L1,atezolizumab,durvalumab,ExoPD-L1,exosomal PD-L1,IHC assays,ipilimumab,nivolumab,PD-L1,pembrolizumab,SP142,SP263
求助PDF
上传PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Related Papers
Cell Communication and Signaling 2023
被引用2
FRONTIERS IN IMMUNOLOGY 2022
被引用0
Cancers 2023
被引用17
Application of Immune Checkpoint Inhibitors in Immunotherapy for Gastric Cancer
Immunotherapy 2023
被引用3
British Journal of Pharmacology 2023
被引用5
Human Immunology 2023
被引用1
Biomarkers to Guide Immunomodulatory Treatment: Where Do We Stand?
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 2023
被引用0
JOURNAL OF CLINICAL MEDICINE 2024
被引用0
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper
GPU is busy, summary generation fails
Rerequest